Repros Therapeutics Inc. (RPRX) Shares Down 4.4%
Repros Therapeutics Inc. (NASDAQ:RPRX)’s share price was down 4.4% during trading on Tuesday . The stock traded as low as $2.12 and last traded at $2.18, with a volume of 204,995 shares. The stock had previously closed at $2.28.
Separately, Zacks Investment Research lowered Repros Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $2.25.
The company has a 50-day moving average of $1.88 and a 200-day moving average of $1.62. The company’s market cap is $51.07 million.
Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Tuesday, August 9th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. On average, equities research analysts predict that Repros Therapeutics Inc. will post ($0.70) earnings per share for the current fiscal year.
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.